What is the primary purpose of this 10-Q filing for Amgen Inc.?

This 10-Q filing provides Amgen Inc.'s unaudited quarterly financial results for the period ending June 29, 2010. It allows investors to monitor the company's financial health, operational performance, and any significant developments or risks since the last annual report.

Where can I find details about Amgen's financial performance in this filing?

Detailed financial performance can be found in the 'CONDENSED CONSOLIDATED STATEMENTS OF INCOME,' 'CONDENSED CONSOLIDATED BALANCE SHEETS,' and 'CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS' within Part I, Item 1 of the filing. The 'MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS' in Item 2 provides crucial context and analysis of these figures.

What are the main risks Amgen is facing, as disclosed in this report?

The primary risks facing Amgen are detailed in Part II, Item 1A under 'RISK FACTORS.' This section would typically cover market competition, patent expirations, regulatory challenges, research and development setbacks, and economic conditions, among other potential business risks.

Are there any significant legal issues mentioned that could impact Amgen's financials?

Yes, Amgen addresses 'LEGAL PROCEEDINGS' in Part II, Item 1. Investors should review this section to understand any ongoing litigation or legal disputes that could have a material financial impact on the company.

AMGN 10-Q Quarterly Report Q2 FY2010 — Revenue, Net Income, EPS

Summary

Amgen Inc. (AMGN) reported its financial results for the second quarter ended June 29, 2010. The company demonstrated solid performance with continued revenue generation and active management of its operating expenses. Investors should note the company's ongoing focus on product sales and the management of its research and development pipeline. While specific figures for revenue and net income are detailed within the filing, the overall trend suggests a company navigating a dynamic pharmaceutical landscape. The Management's Discussion and Analysis section is crucial for understanding the drivers behind the financial performance, including any impacts from product sales, pipeline advancements, and strategic initiatives. Investors should pay close attention to the discussion on liquidity, capital resources, and any significant legal proceedings or risk factors that could influence future operations and financial health.

Financial Highlights

49 data points

Beta

Revenue

$3.80B

0.8% Gross Margin

Net Income

$1.20B

0.3% Net Margin

EPS (Diluted)

$1.25

Total Assets

$40.80B

Cash & Equivalents

$1.71B

Free Cash Flow

$1.39B

Financial Statements

Beta

Revenue	$3.80B
Gross Profit	$3.06B
SG&A Expenses	$986.00M
Operating Expenses	$2.29B
Operating Income	$1.52B
Interest Expense	$147.00M
Net Income	$1.20B
EPS (Basic)	$1.25
EPS (Diluted)	$1.25
Shares Outstanding (Basic)	959.00M
Shares Outstanding (Diluted)	964.00M

Key Highlights

1Amgen Inc. filed its 10-Q for the period ending June 29, 2010, providing an update on its financial condition and results of operations.
2The report includes unaudited condensed consolidated financial statements: Statements of Income, Balance Sheets, and Cash Flows.
3Management's Discussion and Analysis (MD&A) is a key section for investors to understand the operational performance and financial trends.
4The filing addresses legal proceedings, which could represent potential financial or operational risks.
5Risk factors are detailed, offering insights into potential challenges and uncertainties facing the company.
6Information regarding unregistered sales of equity securities and use of proceeds is also presented.
7Key financial statements are supplemented by detailed notes providing further context and explanation.

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions